Fumiaki Koizumi

Tokyo Metropolitan Komagome Hospital — Japan

Medicine · Health Sciences

38h-index4.7kcitations213works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(30), HER2/EGFR in Cancer Research(24), Lung Cancer Treatments and Mutations(18), Cancer Genomics and Diagnostics(18), Cancer, Hypoxia, and Metabolism(17)

Publications213 total

Single-cell transcriptomic profiling of platelet-adherent circulating tumor cells using a microcavity-gel manipulation platform
Journal of Bioscience and Bioengineering·2026
Rapid Recovery and Short‐Term Culture of Gastric Circulating Tumor Cells Using Microcavity Array
Engineering in Life Sciences·2025Open Access
Data from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Data from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Table 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Table 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Figure 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Figure 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Table 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Table 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Figure 2 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Figure 1 from Chemotherapy-Regulated microRNA-125–HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
2023Open Access
Supplementary Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
Supplementary Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
Supplementary Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
Data from Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
Supplementary Tables 1-2 from Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Dysfunction of Poly (ADP-Ribose) Glycohydrolase Induces a Synthetic Lethal Effect in Dual Specificity Phosphatase 22-Deficient Lung Cancer Cells
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Kazuto Nishio(20), Tomohide Tamura(10), Yasuhiro Koh(7), Yuka Kitamura(7), Takeshi Sawada(7), Yasuhiro Matsumura(6), Tokuzo Arao(6), Kenji Tamura(6), Yasufumi Katanasaka(6), Yasuhide Yamada(5), Noboru Yamamoto(5), Tatsu Shimoyama(5), Kan Yonemori(4), Yasuhiro Fujiwara(4), Hiroshi Nokihara(4), Nagahiro Saijo(4), Fumiyuki Takahashi(4), Kazuhisa Takahashi(4), Yasuo Kodera(4), Mayu Yunokawa(4)